PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.

Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.

However, endometrial cancer remains a small use, and Jemperli has other ways to make a bigger splash.

Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.

Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting